201 Elliott Avenue West
344 articles with Omeros Corporation
Omeros Corporation today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the UBS Global Healthcare Conference in New York next week.
Omeros Corporation announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2019
Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual Meeting
Cataract surgery performed using OMIDRIA had lower rates of CME than cataract surgery using postoperative steroids
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter 2019 financial results for the period ended March 31, 2019, on Thursday, May 9, 2019, after the market closes.
Omeros Corporation Announces Presentation of OMIDRIA® Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting
The presentation by Keith A. Walter, M.D., Professor of Ophthalmology at Wake Forest University School of Medicine, is entitled Rate of Pseudophakic Cystoid Macular Edema Using Intraoperative and Topical NSAIDs Alone Without Steroids.
According to a recent BioSpace survey, 93% of respondents are open to a new job for the right opportunity. Are you one of the 93%? If so, keep your eyes open for those opportunities and don't stop looking. You never know what may come your way!
Omeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment
Growing Identification of HSCT-TMA a Focus of Recent Annual Meeting of the European Society for Blood and Marrow Transplantation
Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation
Session Will Focus on Diagnosis of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Omeros Corporation (NASDAQ: OMER), today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2018, which include:
Omeros Corporation, announced that the company will issue its fourth quarter and year-end 2018 financial results for the period ended December 31, 2018, on Friday, March 1, 2019, before the market opens.
Omeros Corporation (Nasdaq: OMER) today announced that, as the company prepares for planned commercialization of OMS721, the United States Adopted Names (USAN) Council, in consultation with the World Health Organization’s International Nonproprietary Names (INN) Expert Committee, has selected for the drug the nonproprietary name “narsoplimab.”
Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA
Patient Data from Existing Single-Arm Study Will Form the Basis for BLA; No Historical Control Required
Former Lilly Biotechnology and Immunology Senior Vice President Drawn by Omeros’ Complement Franchise and Novel-Product Pipeline
Additional Positive Data Reported from Second Cohort in Phase 2 Trial
Broadening OMIDRIA Coverage from Payers and Increasing Funding for OMS721 Commercial Preparations
Omeros Establishes Independent Academic Leadership Committee for its OMS721 Phase 3 Clinical Program in IgA Nephropathy
Committee is Comprised of World Leaders in IgA Nephropathy and Renal Clinical Research
Newly Established Center Will Focus on Complement and Inflammation
Omeros Announces Clinical Strategy to Accelerate Pediatric Development of OMS721 for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)
EMA Confirmed OMS721 Eligibility for European Centralized Marketing Authorization Application Review
Hires Commercial and CMC Heads from Celgene
Omeros Corporation today announced its intention to offer, subject to market and other conditions, $210 million aggregate principal amount of its Convertible Senior Notes due 2023 (the "Notes") in a private offering (the "Offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933